205 related articles for article (PubMed ID: 16998721)
1. Methodology of clinical trials in multiple sclerosis.
Mitsikostas DD
Neurol Sci; 2006 Sep; 27 Suppl 5():S362-4. PubMed ID: 16998721
[TBL] [Abstract][Full Text] [Related]
2. Magnetic resonance imaging metrics and their correlation with clinical outcomes in multiple sclerosis: a review of the literature and future perspectives.
Bar-Zohar D; Agosta F; Goldstaub D; Filippi M
Mult Scler; 2008 Jul; 14(6):719-27. PubMed ID: 18424478
[TBL] [Abstract][Full Text] [Related]
3. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force.
Miller DH; Albert PS; Barkhof F; Francis G; Frank JA; Hodgkinson S; Lublin FD; Paty DW; Reingold SC; Simon J
Ann Neurol; 1996 Jan; 39(1):6-16. PubMed ID: 8572668
[TBL] [Abstract][Full Text] [Related]
4. [Evaluation of follow-up and evolution of multiple sclerosis].
Couvreur G
Rev Neurol (Paris); 2001 Sep; 157(8-9 Pt 2):1143-51. PubMed ID: 11787348
[TBL] [Abstract][Full Text] [Related]
5. MRI as an outcome in multiple sclerosis clinical trials.
Daumer M; Neuhaus A; Morrissey S; Hintzen R; Ebers GC
Neurology; 2009 Feb; 72(8):705-11. PubMed ID: 19073945
[TBL] [Abstract][Full Text] [Related]
6. Outcome measures in multiple sclerosis clinical trials.
Andersson PB; Goodkin DE
Baillieres Clin Neurol; 1997 Oct; 6(3):409-28. PubMed ID: 10101581
[TBL] [Abstract][Full Text] [Related]
7. The use of MRI as an outcome measure in clinical trials.
Li DK; Li MJ; Traboulsee A; Zhao G; Riddehough A; Paty D
Adv Neurol; 2006; 98():203-26. PubMed ID: 16400836
[TBL] [Abstract][Full Text] [Related]
8. Magnetic resonance imaging as a surrogate outcome measure of disability in multiple sclerosis: have we been overly harsh in our assessment?
Goodin DS
Ann Neurol; 2006 Apr; 59(4):597-605. PubMed ID: 16566022
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcome measures in multiple sclerosis.
Amato MP; Portaccio E
J Neurol Sci; 2007 Aug; 259(1-2):118-22. PubMed ID: 17376487
[TBL] [Abstract][Full Text] [Related]
10. MRI to monitor treatment efficacy in multiple sclerosis.
Fazekas F; Soelberg-Sorensen P; Comi G; Filippi M
J Neuroimaging; 2007 Apr; 17 Suppl 1():50S-55S. PubMed ID: 17425736
[TBL] [Abstract][Full Text] [Related]
11. Neuropsychological and MRI measures predict short-term evolution in benign multiple sclerosis.
Portaccio E; Stromillo ML; Goretti B; Zipoli V; Siracusa G; Battaglini M; Giorgio A; Bartolozzi ML; Guidi L; Sorbi S; Federico A; Amato MP; De Stefano N
Neurology; 2009 Aug; 73(7):498-503. PubMed ID: 19641173
[TBL] [Abstract][Full Text] [Related]
12. Clinically benign multiple sclerosis despite large T2 lesion load: can we explain this paradox?
Strasser-Fuchs S; Enzinger C; Ropele S; Wallner M; Fazekas F
Mult Scler; 2008 Mar; 14(2):205-11. PubMed ID: 17986507
[TBL] [Abstract][Full Text] [Related]
13. A composite score to predict short-term disease activity in patients with relapsing-remitting MS.
Sormani MP; Rovaris M; Comi G; Filippi M
Neurology; 2007 Sep; 69(12):1230-5. PubMed ID: 17875911
[TBL] [Abstract][Full Text] [Related]
14. New treatment measurements for treatment effects on relapses and progression.
Tintoré M; Sastre-Garriga J
J Neurol Sci; 2008 Nov; 274(1-2):80-3. PubMed ID: 18822433
[TBL] [Abstract][Full Text] [Related]
15. HLA-DRB1*1501, -DQB1*0301, -DQB1*0302, -DQB1*0602, and -DQB1*0603 alleles are associated with more severe disease outcome on MRI in patients with multiple sclerosis.
Zivadinov R; Uxa L; Bratina A; Bosco A; Srinivasaraghavan B; Minagar A; Ukmar M; Benedetto Sy; Zorzon M
Int Rev Neurobiol; 2007; 79():521-35. PubMed ID: 17531857
[TBL] [Abstract][Full Text] [Related]
16. Advanced magnetic resonance imaging metrics: implications for multiple sclerosis clinical trials.
Zivadinov R
Methods Find Exp Clin Pharmacol; 2009; 31(1):29-40. PubMed ID: 19357796
[TBL] [Abstract][Full Text] [Related]
17. Reconsidering clinical outcomes in Multiple Sclerosis: relapses, impairment, disability and beyond.
D'Souza M; Kappos L; Czaplinski A
J Neurol Sci; 2008 Nov; 274(1-2):76-9. PubMed ID: 18817932
[TBL] [Abstract][Full Text] [Related]
18. [Value of MRI in patients with multiple sclerosis].
Tourbah A
Rev Neurol (Paris); 2001 Sep; 157(8-9 Pt 2):1124-7. PubMed ID: 11787344
[TBL] [Abstract][Full Text] [Related]
19. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.
Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Goretti B; Caniatti L; Di Monte E; Ferrazza P; Brescia Morra V; Lo Fermo S; Picconi O; Luccichenti G;
Mult Scler; 2009 Jul; 15(7):779-88. PubMed ID: 19542262
[TBL] [Abstract][Full Text] [Related]
20. Multiple sclerosis: use of MRI in evaluating new therapies.
Miller DH
Semin Neurol; 1998; 18(3):317-25. PubMed ID: 9817536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
